StratifiCare™ has discovered a panel of biomarkers that are able to determine the risk of Severe Dengue. Through simple laboratory analysis, information on the outcome of the disease can now be determined.
Collect patient’s blood sample
Perform assay using Severe Dengue prediction kit
Determine if patient will go on to develop Severe Dengue
Technology is based on well-established assay platform commonly used in hospitals. No additional training is required for technicians.
Ease of anxiety
Patients and their family members can be informed in advance of disease outcome.
90% sensitivity and 97% specificity.*
* Based on pre-clinical studies.
Save on unnecessary
hospitalization expenses if condition can be managed as an outpatient case.